- Home
- ORGO vs ANTX Comparison
ORGO vs ANTX Comparison
Compare ORGO & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGO | ANTX |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.6M | 172.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ORGO | ANTX |
|---|---|---|
| Price | $0.98 | $3.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $2.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 765.7K | 295.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | 32.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $0.93 | $1.00 |
| 52 Week High | $7.08 | $7.19 |
Technical Indicators
Market Signals| Indicator | ORGO | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.69 | 29.98 |
| Support Level | N/A | $2.87 |
| Resistance Level | $2.57 | $5.15 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 11.21 | 14.64 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.